Matrix metalloproteinases in arthritic disease.
The role of matrix metalloproteinases in the degradative events invoked in the cartilage and bone of arthritic joints has long been appreciated and attempts at the development of proteinase inhibitors as potential therapeutic agents have been made. However, the spectrum of these enzymes orchestrating connective tissue turnover and general biology is much larger than anticipated. Biochemical studies of the individual members of the matrix metalloproteinase family are now underway, ultimately leading to a more detailed understanding of the function of their domain structures and to defining their specific role in cellular systems and the way that they are regulated. Coupled with a more comprehensive and detailed study of proteinase expression in different cells of joint tissues during the progress of arthritic diseases, it will be possible for the future development and application of highly specific proteinase inhibitors to be directed at specific key cellular events.
Murphy
Gillian
G
School of Biological Sciences, University of East Anglia, Norwich, UK. g.murphy@uea.ac.uk
Knäuper
Vera
V
Atkinson
Susan
S
Butler
George
G
English
William
W
Hutton
Mike
M
Stracke
Jan
J
Clark
Ian
I
D001172:Arthritis, Rheumatoid / Q000201:enzymology*; D006801:Humans; D020782:Matrix Metalloproteinases / Q000737:chemistry / Q000378:metabolism*; D017434:Protein Structure, Tertiary
D020782:Matrix Metalloproteinases